OraSure Technologies Azioni (NASDAQ: OSUR)

Ultime notizie per OraSure Technologies (NASDAQ:OSUR) Azioni

OraSure Technologies

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

OraSure Technologies, Inc. - Common Stock

OraSure Technologies Inc

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.5 percent. The company reported quarterly sales of $39.915 million which beat the analyst consensus estimate of $39.019 million by 2.30 percent. This is a 55.25 percent decrease over sales of $89.187 million the same period last year.

Earnings

Earnings Beats

News

OSUR

OraSure Technologies Q3 2024 Adj. EPS $(0.01) Beats $(0.08) Estimate, Sales $39.915M Beat $39.019M Estimate

Disclosed in the latest SEC filing, a significant insider purchase on September 10, involves John Kenny, Board Member at OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>).
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001116463/000106299324016411//Archives/edgar/data/1116463/000106299324016411/0001062993-24-016411-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Kenny increased their investment in OraSure Technologies by purchasing 23,256 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $100,000.
Monitoring the market, OraSure Technologies's shares up by 0.48% at $4.23 during Wednesday's morning.
<h3>About OraSure Technologies</h3>
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
<h3>OraSure Technologies: Delving into Financials</h3>
Negative Revenue Trend: Examining OraSure Technologies's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -36.41% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 45.44%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): OraSure Technologies's EPS reflects a decline, falling below the industry average with a current EPS of -0.01.
</li>
</ul>
Debt Management: OraSure Technologies's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 11.69 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 1.15 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 1.91 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001116463">Check Out The Full List Of OraSure Technologies's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Smart Money Move: John Kenny Grabs $100K Worth Of OraSure Technologies Stock

WIIM

OraSure Technologies shares are trading lower after the company issued Q3 revenue guidance below estimates.

Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a In-Line and raises the price target from $4.5 to $5.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on OraSure Technologies, Raises Price Target to $5

Financial Guidance
The Company is guiding to Q3 2024 revenues of $37 to $41 million, which includes Core revenues of $36 to $39 million and InteliSwab&#xAE; revenues of $1 to $2 million.

Guidance

OraSure Sees Q3 2024 Revenue $37M-$41M Vs $52.13M Estimate

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.03) by 333.33 percent. The company reported quarterly sales of $54.335 million which beat the analyst consensus estimate of $52.132 million by 4.23 percent. This is a 36.41 percent decrease over sales of $85.441 million the same period last year.

OraSure Technologies Q2 2024 Adj. EPS $0.07 Beats $(0.03) Estimate, Sales $54.335M Beat $52.132M Estimate

Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a In-Line and lowers the price target from $5.5 to $4.5.

Evercore ISI Group Maintains In-Line on OraSure Technologies, Lowers Price Target to $4.5

JP Morgan analyst Casey Woodring maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a Neutral and lowers the price target from $7 to $6.

JP Morgan Maintains Neutral on OraSure Technologies, Lowers Price Target to $6

OraSure Sees Q2 2024 Revenue $50M-$55M Vs $53.7M Estimate

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 91.49 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $54.132 million which beat the analyst consensus estimate of $52.102 million by 3.90 percent. This is a 65.07 percent decrease over sales of $154.963 million the same period last year.

OraSure Technologies Q1 2024 Adj EPS $0.04 Beats $0.01 Estimate, Sales $54.132M Beat $52.102M Estimate

Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a In-Line and lowers the price target from $7 to $6.5.

Evercore ISI Group Maintains In-Line on OraSure Technologies, Lowers Price Target to $6.5

OraSure Technologies shares are trading higher after the company reported better-than-expected Q4 financial results.

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
OraSure Technologies beat estimated earnings by 175.0%, reporting an EPS of $0.22 versus an estimate of $0.08.
Revenue was down $47.20 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.23 which was followed by a 3.0% increase in the share price the next day.
Here's a look at OraSure Technologies's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>-0.08</td>
<td>0.14</td>
<td>-0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.09</td>
<td>0.47</td>
<td>0.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>74.96M</td>
<td>63.86M</td>
<td>126.57M</td>
<td>97.10M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>89.19M</td>
<td>85.44M</td>
<td>154.96M</td>
<td>123.08M</td>
</tr>
</tbody>
</table>

To track all earnings releases for OraSure Technologies <a href="https://www.benzinga.com/quote/OSUR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OraSure Technologies: Q4 Earnings Insights

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.09 by 144.44 percent. The company reported quarterly sales of $75.88 million which beat the analyst consensus estimate of $74.12 million by 2.38 percent. This is a 38.35 percent decrease over sales of $123.08 million the same period last year.

OraSure Technologies Q4 2023 Adj EPS $0.22 Beats $0.09 Estimate, Sales $75.88M Beat $74.12M Estimate

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.
Analysts estimate that OraSure Technologies will report an earnings per share (EPS) of $0.08. 
OraSure Technologies bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.23, which was followed by a 2.87% increase in the share price the next day.
Here's a look at OraSure Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>-0.08</td>
<td>0.14</td>
<td>-0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.09</td>
<td>0.47</td>
<td>0.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>32.0%</td>
<td>5.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708963313_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of OraSure Technologies were trading at $6.96 as of February 23. Over the last 52-week period, shares are up 10.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OSUR/earnings">To track all earnings releases for OraSure Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: OraSure Technologies's Earnings

Contracts

OraSure Technologies Announced It Is Leading The Series B Financing And Has Penned Wide-ranging Strategic Distribution Deals With Sapphiros And Certain Of Its Related Entities

Citigroup analyst Patrick Donnelly maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a Buy and raises the price target from $7 to $9.

Citigroup Maintains Buy on OraSure Technologies, Raises Price Target to $9

As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>OraSure Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/osur#NASDAQ">OSUR</a>)</h3>
<ul>
<li>OraSure Technologies posted upbeat quarterly results. &ldquo;We continue to make progress on our transformation journey by &lsquo;innovating and operating with disciplined execution and accountability&rsquo;. During the third quarter, we generated significant positive operating cash flow with margin expansion, driven by our enterprise-wide focus on operational efficiency,&rdquo; said OraSure President and CEO Carrie Eglinton Manner. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/OSUR">52-week high of $7.82. </a>.</li>
<li>RSI Value: 77.78</li>
<li>OSUR Price Action: Shares of OraSure Technologies fell 0.6% to close at $6.90 on Thursday.</li>
</ul>
<h3>POINT Biopharma Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pnt#NASDAQ">PNT</a>)</h3>
<ul>
<li>The company posted net loss of $24.8 million, or $0.23 per share, for the three months ended Sept. 30, 2023. &ldquo;The founding mission of our company is to accelerate the discovery, development and global access to radiopharmaceuticals,&rdquo; said Joe McCann, Ph.D., CEO of POINT Biopharma. &ldquo;I view Lilly&rsquo;s agreement to acquire POINT as validation of the uniqueness of our team, infrastructure and pipeline. Together, we can become a global radiopharmaceutical leader, executing on our mission and transforming lives touched by cancer.&quot; The company&rsquo;s <a href="https://www.benzinga.com/quote/PNT"> stock has a 52-week high </a> of $13.55.</li>
<li>RSI Value: 74.75</li>
<li>PNT Price Action: Shares of POINT Biopharma Global fell 0.5% to close at $13.33 on Thursday.</li>
</ul>
<h3>Natera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntra#NASDAQ">NTRA</a>)</h3>
<ul>
<li>Natera has entered into an agreement with Merck, under which Merck will utilize Natera&#39;s real-world database to advance oncology research. The company has a <a href="https://www.benzinga.com/quote/NTRA"> 52-week high </a> of $63.00.</li>
<li>RSI Value: 71.60</li>
<li>NTRA Price Action: Shares of Natera fell 0.3% to close at $52.81 on Thursday.</li>
</ul>
<h3>Doximity, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docs#NYSE">DOCS</a>)</h3>
<ul>
<li>Doximity reported better-than-expected second-quarter financial results and issued revenue guidance above estimates. &quot;We&rsquo;re proud to make medicine mobile, with another quarter of record engagement across our entire platform,&quot; said Jeff Tangney, co-founder and CEO of Doximity. The company&rsquo;s 52-week high is $40.12.</li>
<li>RSI Value: 70.05</li>
<li>DOCS Price Action: Shares of Doximity closed at $25.40 on Thursday.</li>
</ul>
<h3>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>)</h3>
<ul>
<li>Hims &amp; Hers reported better-than-expected third-quarter sales results, raised FY23 guidance above estimates and announced a $50 million share repurchase program. &quot;I am proud of the progress made across several of our key pillars in the third quarter which meaningfully moved Hims &amp; Hers one step closer toward our vision of an accessible, personalized platform,&quot; said Andrew Dudum, co-founder and CEO. The company <a href="https://www.benzinga.com/quote/HIMS"> has a 52-week high </a> of $12.34.</li>
<li>RSI Value: 71.22</li>
<li>HIMS Price Action: Shares of Hims &amp; Hers Health settled at $7.71 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/23/11/35843238/bjs-wholesale-club-gap-and-3-stocks-to-watch-heading-into-friday"> BJ&#39;s Wholesale Club, Gap And 3 Stocks To Watch Heading Into Friday </a>

Short Ideas

Small Cap

Pre-Market Outlook

Markets

DOCS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NTRA

Top 5 Health Care Stocks That May Collapse In November

JP Morgan analyst Tycho Peterson maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a Neutral and lowers the price target from $6 to $5.

JP Morgan Maintains Neutral on OraSure Technologies, Lowers Price Target to $5

OraSure Technologies Q2 2024 Earnings Preview

OraSure Technologies Non-GAAP EPS of $0.07 beats by $0.04, revenue of $54.34M beats by $2.21M

An update from Orasure Technologies (OSUR) is now available. In a recent webcast, the management of the Company, including CEO Carrie Eglinton Mann...

Orasure Technologies Discusses Quarterly Financials and Business Updates

OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OraSure Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/osur-stock-quote/">OSUR</a>) just reported results for the second quarter of 2024.<ul><li>OraSure Technologies reported earnings per share of 7 cents. This was above the analyst estimate for EPS of -3 cents.</li><li>The company reported revenue of $54.34 million.</li><li>This was 4.23% better than the analyst estimate for revenue of $52.13 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/osur-stock-earnings-orasure-technologies-for-q2-of-2024/">OSUR Stock Earnings: OraSure Technologies Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OSUR Stock Earnings: OraSure Technologies Beats EPS, Beats Revenue for Q2 2024

J.P. Morgan analyst Casey Woodring maintained a Hold rating on Orasure Technologies (OSUR – Research Report) on August 9 and set a price target of ...

J.P. Morgan Sticks to Their Hold Rating for Orasure Technologies (OSUR)

The latest update is out from Orasure Technologies ( ($OSUR) ). OraSure Technologies, Inc. has expanded its Board of Directors from six to seven me...

OraSure Technologies Appoints New Independent Director

OraSure Technologies: Nursing A COVID-19 Hangover

OraSure Technologies Non-GAAP EPS of -$0.01 beats by $0.01, revenue of $39.92M beats by $0.9M

OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript

FLGT

Press Releases

Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX

OraSure Reports Q1 '24 Revenue of $54.1 Million

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

OraSure Technologies Supports National HIV Testing Day

OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th

OraSure Reports Q2 '24 Revenue of $54.3 Million

Health Care

Management

OraSure Technologies Elects Jack Kenny to the Board of Directors

OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th

OraSure Reports Q3 '24 Revenue of $39.9 Million

OraSure to Participate in Upcoming Investor Conference

ADTN

ALTR

ATNI

BMRN

CRNC

CRWD

GDDY

HOUS

IART

ILMN

INBS

KRYS

NFBK

PENN

SPGI

STEP

TTEC

VIRT

WERN

XPER

Align Tech

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

Rockwell Medical

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

WORK Medical Technology Group LTD - Ordinary Shares

WORK Medical Technology

Comments

OraSure Technologies

Notizie

Ultime notizie per OraSure Technologies (NASDAQ:OSUR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO